Key Developments: Coloplast A/S (CLPBY.PK)
--USD
--
-- (--)
--
--
--
--
--
--
--
--
Latest Key Developments (Source: Significant Developments)
Coloplast A/S Announces Extraordinary Dividend and Confirms FY 2012/2013 Guidance
Coloplast A/S announced that its Board of Directors has resolved that Coloplast is to pay an extraordinary dividend of DKK 3 per share for a total dividend payout of DKK 634 million. In addition, the Company decided to confirm its guidance for the fiscal year 2012/2013. The Company expects organic revenue growth of between 6% and 7% and growth of between 5% and 6% in DKK, as well as EBIT margin of between 31% and 32%, both at constant exchange rates and in DKK. For the fiscal year 2011/2012, the Company reported revenue of DKK 11,023.00 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of DKK 11,663.96 million for the fiscal year 2012/2013. Full Article
Coloplast A/S Initiates Second Part of Share Buy-Back Program
Coloplast A/S announced that it is initiating the second part of the share buy-back program. The second part of DKK 500 million is expected to run from February 25, 2013 to August 30, 2013 at the latest. The first part of the program, also of DKK 500 million, was executed in 2011/2012 fiscal year. The second part of the program is subject to these terms: the purpose of the program is to reduce share capital and to meet obligations from employee share option programs; total number of B shares to be repurchased in second part of the program will not be higher than (i) a number with a total purchase price of DKK 500 million and (ii) 1,900,000 B shares; based on current share price the approximate number of B shares expected to be acquired under the program is 1,695,000 B shares of DKK 1 each at a total nominal value of DKK 1,695,000, equivalent to 0.8% of share capital of the Company; the maximum number of shares that can be bought within the scope of the existing 10% authority is approximately further 13,463,000 shares of DKK 1 each at a total nominal value of DKK 13,463,000; the maximum number of company shares to be purchased per daily market session will not be greater than 25% of average daily volume of shares traded on NASDAQ OMX Copenhagen during preceding 20 trading days; during the program no shares will be purchased at a price exceeding the higher of the two prices: the price of last independent trade and the highest current independent bid on NASDAQ OMX Copenhagen. Full Article
Coloplast A/S Comments On FY 2012/13 Organic Revenue Guidance
Coloplast A/S announced that for fiscal 2012/13, it expects 6-7% organic revenue growth and 5-6% in DKK. Full Article
Coloplast A/S Proposes Extraordinary Dividend Authorization
Coloplast A/S announced that its Board of Directors proposed to the Annual General Meeting that the Board of Directors is authorized to pay extraordinary dividend in accordance with the rules of the Danish Companies Act. Full Article
Coloplast A/S Proposes FY 2011/2012 Dividend of DKK 20 per Share; Issues FY 2012/2013 Revenue Guidance in Line with Analysts' Estimates; Issues FY 2012/2013 EBIT Margin Guidance
Coloplast A/S announced that its Board of Directors proposed that the shareholders attending the general meeting of the Company to be held on December 11, 2012 approve the proposal to pay a dividend of DKK 20 per share for fiscal year 2011/2012. For fiscal year 2010/2011 the Company paid a dividend of DKK 14. The Company also announced fiscal year 2012/2013 financial guidance. The Company expects to report fiscal year 2012/2013 revenue growth in a range of between 6% and 7% both organically and in DKK. It also expects to report fiscal year 2012/2013 EBIT margin in a range of between 31% and 32% both at constant exchange rates and in DKK. The Company reported fiscal year 2011/2012 revenue of DKK 11,023 million. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2012/2013 revenue of DKK 11,708.32 million. Full Article
Coloplast A/S Reaffirms FY 2011/12 Organic Revenue Guidance
Coloplast A/S announced that in the financial year 2011/12, it continue to expect organic revenue growth of about 6% and of about 8% in DKK. Full Article
Coloplast A/S's Subsidiary Wins Patent Infringement Case
Coloplast A/S announced that its North American subsidiary has won an infringement case against Generic Medical Devices for Coloplast's urology patents. The ruling was made in a court in Tacoma, Washington, the United States, and it stated that Generic Medical Devices was infringing on Coloplast's urology care patent. Full Article
Coloplast A/S Maintains FY 2011/2012 Organic Revenue Growth Guidance and Raises FY 2011/2012 EBIT Margin Guidance
Coloplast A/S announced that it continues to expect to report fiscal year 2011/2012 organic revenue growth of approximately 6% and of approximately 8% in DKK based on current exchange rates. The Company also announced that it has raised its fiscal year 2011/2012 EBIT margin guidance from approximately 27% to approximately 28% at constant exchange rates, and from approximately 28% to approximately 29% in DKK based on current exchange rates. The Company also still expects to report fiscal year 2011/2012 capital expenditure to be approximately DKK 300 million and fiscal year 2011/2012 effective tax rate in a range of between 25% and 26%. Full Article
Coloplast A/S Announces Update on Share Repurchase Program
Coloplast A/S announced that it has launched a share buy-back program for up to DKK 1 billion. The first part of the program, of DKK 500 million, is expected to take place during the period from February 1, 2012 to September 30, 2012. The second stage of the program is expected to take place from October 1, 2012 to September 30, 2013. Full Article
Coloplast A/S Maintains FY 2011/2012 Revenue and EBIT Guidance
Coloplast A/S announced that for the fiscal year 2011/2012 it still expects an organic revenue growth of about 6% and revenue growth for the fiscal year 2011/2012 in DKK (Danish kroner) is now expected to be about 8%. In addition, the Company still expects a financial year 2011/2012 EBIT margin of about 27% at constant exchange rates while the fiscal year 2011/2012 EBIT margin in DKK is now expected to be about 28%. Capital expenditure in the fiscal year 2011/2012 is expected to be around DKK 300 million. The effective tax rate in the fiscal year 2011/2012 is expected to be between 25% and 26%. Full Article
UPDATE 1-Denmark's Coloplast to pay special dividend, shares jump
COPENHAGEN, April 30 - Shares in Danish healthcare product maker Coloplast jumped almost 5 percent on Tuesday after it announced a one-off dividend, rewarding shareholders after quarterly earnings grew in all of its business units.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
